Technology News and Research

RSS

Study to determine the expression of S100A2 and p63 genes

As a member of the S100 family, S100A2 is considered a candidate tumor-suppressor gene. Recently, p63 gene, a new member of the p53 gene family, has been studied in the fields of tumorigenesis, cell apoptosis and tissue growth. At present, few studies have been carried out on the expression and relationship of S100A2 and p63 in EC.

18 Sep 2009

Zargis Medical receives FDA approval for marketing Signal X6 device

Zargis Medical Corp., a spin-off from Siemens Corporate Research and a majority-owned subsidiary of Speedus Corp., announced today it has received U.S. Food and Drug Administration (FDA) clearance to market its new Signal X6(TM) device.

18 Sep 2009

Disaster recovery program for schools

EdOptions (www.edoptions.com), an award-winning educational technology company, announced today that it will offer schools a built-in disaster recovery plan to provide an affordable, accessible strategy for educators to help ensure the continuity of learning.

18 Sep 2009

New patent grant for oligonucleotide modulators of blood coagulation factor aptamers

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual property estate.

18 Sep 2009

Chairman Baucus' effort on health care reform applauded

"We are pleased that Chairman Baucus' bill is a meaningful step forward toward health insurance coverage for all Americans. We look forward to working with the chairman and senators to ensure the very best enrollment strategy for connecting to coverage all those who need it.

18 Sep 2009

National Research Council's report emphasizes on launching of a new multidisciplinary initiative

A report released today by the National Research Council calls on the United States to launch a new multiagency, multiyear, and multidisciplinary initiative to capitalize on the extraordinary advances recently made in biology and to accelerate new breakthroughs that could solve some of society's most pressing problems -- particularly in the areas of food, environment, energy, and health.

18 Sep 2009

Solos obtains purchase order for surgical endoscopy instruments

Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has received multiple purchase orders for its MammoView(TM) line of surgical endoscopy instruments from the National Cancer Institute (NCI), Bethesda MD.

18 Sep 2009

Juvaris BioTherapeutics completes first close on Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).

18 Sep 2009

CTI project to enhance child nutrition in Malawi and Tanzania

A McKnight Foundation grant recently awarded to Compatible Technology International (CTI), Tanzania's Sokoine University of Agriculture (SUA) and the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) will address these needs. The organizations are combining their expertise for a four-year $673,000 research and development grant project, which will focus on enhancing child nutrition and the livelihoods of rural households in Malawi and Tanzania.

18 Sep 2009

Genome technology to examine brown tides on the East Coast

NOAA has awarded Massachusetts-based Woods Hole Oceanographic Institution $120,000 as part of an anticipated three-year, nearly $500,000 project, to determine how nitrogen and phosphorus promote brown tides on the East Coast. Funds were awarded through the interagency Ecology and Oceanography of Harmful Algal Blooms (ECOHAB) program.

18 Sep 2009

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

Griffin Securities' report features stem cell hypothesis of cancer

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by Griffin Securities, a New York-based brokerage firm, highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments.

18 Sep 2009

Drug carrier that cuts off blood supply to tumors

To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.

18 Sep 2009

Research reveals that iPSCs similar to embryonic stem cells

A team of researchers from the University of California, San Diego School of Medicine and the Salk Institute for Biological Studies in La Jolla have developed a safe strategy for reprogramming cells to a pluripotent state without use of viral vectors or genomic insertions. Their studies reveal that these induced pluripotent stem cells (iPSCs) are very similar to human embryonic stem cells, yet maintain a "transcriptional signature." In essence, these cells retain some memory of the donor cells they once were.

18 Sep 2009

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.

18 Sep 2009

Wound Management Technologies acquires BioPharma

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that it has completed the acquisition of BioPharma Management Technologies, Inc., a privately held biotechnology company with a platform of proprietary and patented technologies for topical pain management and resorbable orthoses.

18 Sep 2009

Merge Healthcare launches FusionWeb application software

Continuing its technology leadership in image-enabling the healthcare enterprise, Merge Healthcare, today announced the release of FusionWeb™, a revolutionary zero-client software platform that enables secure

18 Sep 2009

Employers to reexamine health benefit strategies in response to passage of health care reform legislation

With health care reform efforts ramping up after the summer break, many of the nation’s employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.

18 Sep 2009

Calypso Medical raises funds for commercial expansion

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced the completion of a $50 million round of venture capital financing, led by Skyline Ventures and Frazier Healthcare Ventures.

18 Sep 2009

UCSF chooses Think First to support revenue cycle performance

Think First, a premier provider of revenue cycle services, has been chosen by the University of California San Francisco (UCSF) Medical Group to support their efforts to improve revenue cycle performance.

17 Sep 2009